Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-04-20 1:03 pm Purchase | 2023-03-14 | 13D | RepliCel Life Sciences Inc. REPCF | Schutte Andrew | 25,104,422 34.530% | 6,480,416 (+34.80%) | Filing History |
| 2023-01-26 10:50 am Purchase | 2022-12-30 | 13D | RepliCel Life Sciences Inc. REPCF | Schutte Andrew | 18,624,006 31.170% | 10,272,471 (+123.00%) | Filing History |
| 2023-01-05 2:22 pm Purchase | 2022-12-30 | 13D | RepliCel Life Sciences Inc. REPCF | MACKAY JAMIE MYLES | 8,864,037 16.410% | 2,025,000 (+29.61%) | Filing History |
| 2022-09-28 6:08 pm Purchase | 2022-05-04 | 13D | RepliCel Life Sciences Inc. REPCF | MACKAY JAMIE MYLES | 6,839,037 15.220% | 6,839,037 (New Position) | Filing History |
| 2022-06-02 1:39 pm Purchase | 2022-05-04 | 13D | RepliCel Life Sciences Inc. REPCF | Schutte Andrew | 8,351,535 18.550% | 3,724,184 (+80.48%) | Filing History |
| 2021-12-21 3:08 pm Purchase | 2021-12-17 | 13D | RepliCel Life Sciences Inc. REPCF | MAINPOINTE PHARMACEUTICALS LLC | 3,986,687 10.340% | 1,479,885 (+59.03%) | Filing History |
| 2021-06-03 6:46 pm Purchase | 2021-04-23 | 13D | RepliCel Life Sciences Inc. REPCF | MAINPOINTE PHARMACEUTICALS LLC | 2,506,802 6.770% | 2,506,802 (New Position) | Filing History |